Literature DB >> 11012438

Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis.

P Reimer1, N Jähnke, M Fiebich, W Schima, F Deckers, C Marx, N Holzknecht, S Saini.   

Abstract

PURPOSE: To determine the accuracy for detection and characterization of focal hepatic lesions of nonenhanced, superparamagnetic iron oxide (SPIO)-enhanced, or a combination of nonenhanced and SPIO-enhanced MR imaging and contrast-enhanced spiral computed tomography (CT).
MATERIALS AND METHODS: Spiral CT and T2-weighted SPIO-enhanced (ferucarbotran-enhanced) MR imaging were performed in 35 patients within 2 weeks before surgery for malignant hepatic lesions. Only malignant lesions with histopathologic proof were considered. A total of 875 images with and 800 images without focal lesions were presented to five readers, who were asked to assess the presence and characterization of lesions by using a five-point confidence scale. Receiver operating characteristic analysis was performed.
RESULTS: Nonenhanced and SPIO-enhanced images together and SPIO-enhanced images alone yielded the best performance for lesion detection. No differences were found among all imaging techniques with regard to lesion characterization (benign vs malignant). The combined approach resulted in larger area under the ROC curve (A(z) = 0.9062) and accuracy (85.3%) (P < 0.02), as compared with SPIO-enhanced MR imaging (A(z) = 0.8667; accuracy, 73.1%).
CONCLUSION: SPIO-enhanced T2-weighted MR imaging was more accurate than nonenhanced T1-weighted and T2-weighted MR imaging and contrast-enhanced spiral CT for the detection of focal hepatic lesions. The combined analysis of nonenhanced and SPIO-enhanced images was more accurate in the characterization of focal hepatic lesions than was review of SPIO-enhanced images alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012438     DOI: 10.1148/radiology.217.1.r00oc31152

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

Review 1.  What is the current situation in liver imaging?

Authors:  M M Uggowitzer
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

2.  Intra-individual comparison of image contrast in SPIO-enhanced liver MRI at 1.5T and 3.0T.

Authors:  Marcus von Falkenhausen; Carsten Meyer; Götz Lutterbey; Nuschin Morakkabati; Oliver Walter; Jürgen Gieseke; Renate Blömer; Winfried A Willinek; Christiane K Kuhl; Hans H Schild
Journal:  Eur Radiol       Date:  2006-12-15       Impact factor: 5.315

3.  Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography.

Authors:  Riccardo Lencioni; Clotilde Della Pina; Jordi Bruix; Pietro Majno; Luigi Grazioli; Giovanni Morana; Antonella Filippone; Andrea Laghi; Carlo Bartolozzi
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

4.  Magnetic nanoparticles and their applications in image-guided drug delivery.

Authors:  Mi Kyung Yu; Jinho Park; Sangyong Jon
Journal:  Drug Deliv Transl Res       Date:  2012-02       Impact factor: 4.617

5.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

Review 6.  Using Nanoparticles in Medicine for Liver Cancer Imaging.

Authors:  Farideh Farokhi Moghadam
Journal:  Oman Med J       Date:  2017-07

Review 7.  [Diagnostic imaging of liver tumours. Current status].

Authors:  B Boozari; J Lotz; M Galanski; M Gebel
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

8.  Detection of hepatic metastases by superparamagnetic iron oxide-enhanced MR imaging: prospective comparison between 1.5-T and 3.0-T images in the same patients.

Authors:  Keitaro Sofue; Masakatsu Tsurusaki; Mototaka Miyake; Aine Sakurada; Yasuaki Arai; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2010-04-29       Impact factor: 5.315

9.  Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

Authors:  Yi-Xiang J Wang
Journal:  Quant Imaging Med Surg       Date:  2011-12

Review 10.  Contrast agents for hepatic MRI.

Authors:  Giovanni Morana; Elisabetta Salviato; Alessandro Guarise
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.